Our research and data collection efforts are brought together under the WFH Research and Data Collection Program, which includes the Annual Global Survey, the World Bleeding Disorders Registry, the Gene Therapy Registry, and their accompanying education and capacity building programs. Our objective is to provide national member organizations (NMOs) and hemophilia treatment centres (HTCs) with the tools to increase their capacity, the framework to collect data on people with bleeding disorders, and the education and training to use that data to conduct research and advocate for better care.
The Annual Global Survey is a yearly cross-sectional survey of WFH national member organizations (NMOs) that includes country-level demographic and treatment-related data on people with hemophilia (PWH), von Willebrand disease (VWD), rare factor deficiencies, and inherited platelet disorders.
Data Collection for the Annual Global Survey 2021 has officially begun! We are now collecting data for 2021 Annual Global Survey. For any questions or comments regarding the 2021 Annual Global Survey, please email [email protected].
Important Dates | |
Data submission deadline | May 31 |
Data and Demographics Committee preliminary review | July |
Final validaton of country data | July 30 |
Publication of the Report on the Annual Global Survey | October |
In the report on the Annual Global Survey 2020, there were a total of 120 data respondents who provided demographic and treatment information on PWH. This report illustrates that globally over time, there have been over 393,000 PWBD identified and reported. Furthermore, new tables have been added to show the number of patients being treated with FVIIIa and FEIBA, as well as products used to treat VWD. The WFH is appreciative of all the efforts our national member organizations (NMOs) made in gathering this important data.
Please credit the WFH when Annual Global Survey data are used in presentations, publications, or other research material. We encourage researchers to contact us when they use WFH Annual Global Survey data. Any questions or comments related to the survey can be addressed to [email protected].
The WFH has developed interactive and informative visualizations to summarize Annual Global Survey data. This system allows for easier and faster analysis and report creation. View and download graphs of Annual Global Survey data using our new system.
For more information, contact [email protected].
The WFH Annual Global Survey mini reports are advocacy tools that provide more in-depth perspective and context to Annual Global Survey data.
The WBDR is the only global registry collecting standardized clinical data on people with hemophilia (PWH). The WBDR provides a web-based data entry platform to a large network of participating hemophilia treatment centres (HTCs) to collect and manage their data. WBDR data are invaluable for evidence-based advocacy, research, and improving clinical practice.
The WBDR is a key data collection tool improving the provision of care for PWH around the world.
HTCs interested in participating in the WBDR need to meet the following criteria:
If your HTC is interested in participating in the WBDR, please email us at [email protected]. The WFH will guide you through the process of obtaining ethics approval from your local institution or ministry of health.
Once HTCs have obtained ethics approval, the individual(s) who will be doing data entry must take a WBDR data entry training before they can start enrolling patients.
The International Data Integration Program helps to combine resources from existing hemophilia registries and maximize the utility of data that currently exist by facilitating data transfer from existing patient registries to the WBDR. The program is available to interested countries who wish to join this global initiative by sharing their national data and having their data represented in the WBDR. Contact the WFH at [email protected] for more information.
Participating in the WBDR allows PWH to play an active role in building this important resource and improving the future of global hemophilia care. If you are a PWH, or a caregiver of a PWH, and are interested in enrolling in the WBDR, please contact your HTC and inquire about their participation in the WBDR.
The WBDR database was developed through a collaboration between the WFH, the Karolinska Institute, and Health Solutions.
The WBDR was launched in 2018 with a minimal data set, and an extended data set was added to the database in March 2019. Additionally, the WBDR includes five functional scales and a quality of life scale.
All patient information stored in the WBDR is de-identified and confidential. The data policy guidelines of Health Solutions adhere to both the CE-mark (Conformité Européenne) and the U.K. IGSoC (Information Governance Statement of Compliance) standards, and are compliant with the General Data Protection Regulation (GDPR).
The WBDR 2021 Data Report includes demographic and clinical data on more than 9,000 patients from 104 HTCs and 37 countries. Please credit the WFH when WBDR data are used in presentations, publications, or other research materials.
Previous reports:
The WFH offers three WBDR programs to help HTCs collect quality data and conduct research studies using WBDR data.
The WBDR offers a comprehensive Data Quality Accreditation (DQA) Program. The Program includes a robust data cleaning and validation process that is used to enhance the data completeness, accuracy, and consistency. The WBDR data quality team works with all HTCs, providing training and feedback on the quality of collected data.
The WBDR Research Support Program (RSP) is designed to motivate and support WBDR HTCs to collect, analyze, and use their WBDR data. The goal is to encourage countries with limited data collection experience to participate in the WBDR and use their data for research and advocacy.
The WBDR HTC Funding Program (HFP) is designed to provide funds to support data collection activities at WBDR HTCs in low and lower-middle income countries. The Program aims to help HTCs improve patient enrolment and improve the quality and completeness of entered data.
For more information on data entry in the WBDR, participating HTCs are invited to consult the documents below.
If you have any questions, we invite you to check the WBDR FAQs or contact us at: [email protected]
Provides funding for data entry activities at participating HTCs
Annual Report summarizing demographic and clinical data from participating countries
To each person with a bleeding disorder who has kindly agreed to share their data: thank you for helping improve the quality of care for people with bleeding disorders (PWBDs) around the world.
To each of the WBDR HTCs: thank you to all of the dedicated staff at participating HTCs who work hard to ensure that their data is meeting WBDR data quality standards.
The WFH thanks all of our sponsors for their generous financial support which allows us to continue to develop this important initiative. The WBDR is supported by funding from:
The Gene Therapy Registry (GTR) is a prospective, observational, and longitudinal registry designed to collect long-term data on people with hemophilia (PWH) who receive gene therapy.
Gene therapy is a new and evolving therapeutic modality for hemophilia. Clinical trials have established the efficacy of gene therapy in decreasing bleeding and use of hemostatic treatment for at least five to eight years post-infusion. However, many unresolved questions on the long-term safety, variability and durability of efficacy remain at the completion of initial clinical trial programs. Lifelong follow‐up of patients is crucial to monitor long-term safety and efficacy of gene therapy.
The primary objective of the GTR is to determine the long-term safety of factor VIII and factor IX gene therapies for PWH. Secondary objectives are to determine the long-term efficacy and the durability of factor VIII and factor IX gene therapies in PWH, and to assess long-term quality of life and burden of disease post gene-therapy infusion.
Data will be captured in the registry one of two ways:
If participation in the GTR is of interest to your HTC or to your country, please contact us at [email protected].
The GTR protocol synopsis is available here.
Data Quality Program
The WFH GTR will include a comprehensive data quality program, which will be applied to all WFH GTR data entered in the gene therapy registry. All data will be evaluated on the following data quality dimensions:
For more information on participating in the GTR, PWH and HTCs are invited to consult the documents below:
Publications prepared by the GTR Steering Committee are available here:
Did you know?
The WFH VWD Initiative Program aims to improve diagnosis and clinical management of VWD and increase the awareness of VWD in lay and medical communities.
Keep up to date on the latest developments in the bleeding disorders community, from medical advances to important events.
The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.
Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.
References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.
The WFH does not collect personally identifying information about you when you visit our site, unless you choose to provide such information to us. Providing such information is strictly voluntary. This policy is your guide to how we will handle information we learn about you from your visit to our website.
Throughout our website, we provide links to other servers which may contain information of interest to our readers. We take no responsibility for, and exercise no control over, the organizations, views, or accuracy of the information contained on other servers. When linking to the WFH, we request that you ensure that there are no associated connections for commercial purposes. Any official use of the name WFH or the use of its logo needs to be approved by the WFH. If you have a link you’d like us to consider adding to our website, please send an email to [email protected] with the subject “Link request.”
All information, photographs, graphics, and other material on this website are protected by copyright. While users of this website may use the content for personal, non-commercial use, none of the content of this website can be modified, translated, transferred or sold, copied, reproduced, published, or distributed, in whole or in part, without the prior written consent of the WFH. To view a copy of the WFH’s permissions guidelines, click here.
The WFH encourages the dissemination of its information and welcomes proposals on the reprinting, redistribution, and translation of its materials. If you would like to publish information that you find on our website, please send your request to [email protected].
If you have suggestions on how to make the site more accessible, please contact us at [email protected].
Our website provides users the opportunity to opt-out of receiving communications from us through a special online form or via the communication they have received. You may, at all times, choose to receive which communications within the organization you can receive or none at all. You may also update your contact information previously provided to us via another online form.
If you have any questions about this privacy statement, the practices of this site, or your dealings with this website, you can contact us at [email protected].
The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.
If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).
We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.
Recognizing that training women leaders ensures the diversity our community need to thrive; the Hemophilia Alliance has been a longtime supporter of the Susan Skinner Memorial Fund. They deepened their engagement with the global community through the establishment of the Travel Grant Program, which allows US-based multidisciplinary healthcare professionals the opportunity to attend WFH global training workshops. The wealth of experience and perspective attendees bring back home to their communities helps patients across the country. Their patience and support as we grappled with changing norms in these challenging times gave us the flexibility to meet our community’s needs with revamped programming.
National Hemophilia Center, Tel Hashomer
Sheba Medical Center
Hospital Universitario La Paz
Haemostasis and Thrombosis Unit
Haematology Service, University and Polytechnic Hospital
Haemophilia Comprehensive Care Centre
Charlotte Maxeke Johannesburg Academic Hospital
Singapore General Hospital Haemophilia Treatment Clinic
Centre International de Traitement de l’Hémophilie (CITH) de Dakar
Centre National de Transfusion Sanguin (CNTS)
National Medical Research Center of Hematology of the Russian Academy of Medical Sciences
Van Creveldkliniek
University Medical Centre Utrecht
Nara Hemophilia Centre
Nara Medical University
Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
National Institute of Immunohaematology (ICMR) and KEM Hospital
Christian Medical College, Vellore
International Hemophilia Training Center – Bangkok
Ramathibodi Hospital
Mahidol University
Paris Haemophilia Centre (Necker (N) and Kremlin Bicetre (KB) Hospitals)
Shabrawishi Hospital, Egyptian Society of Hemophilia, and Cairo University
University of Toronto Hemophilia Centres
St. Michael’s Hospital
Hemocentro – “Unidade de Hemofilia Cláudio Luiz Pizzigatti Corrêa”
Hemocentro Unicamp, University of Campinas
Haemostasis and Thrombosis Unit
Division of Haematology
Cliniques universitaires Saint-Luc
Hemofiliecentrum Leuven, University of Leuven
Medical University of Vienna
Department of Medicine I
Clinical Division of Hematology and Hemostaseology
Ronald Sawers Haemophilia Centre
Instituto Asistencial “Dr. Alfredo Pavlovsky”
(Fundación de la Hemofilia)
Instituto De Investigaciones Hematológicas “Dr. Mariano R. Castex” (IIHEMA
(Academia Nacional de Medicina)
The WFH was established in 1963 by Frank Schnabel, a Canadian businessman born with severe hemophilia A. He believed that patient organizations could be much more effective—and do more to represent the interests of people living with bleeding disorders—if they worked together. The first WFH Congress was held in Copenhagen, Denmark, on June 25, 1963, and was attended by representatives from 12 countries. Now, the WFH and our global network of national member organizations (NMOs) represent the interests of people with hemophilia and other inherited bleeding disorders in 147 nations.
Malmö Centre for Thrombosis and Haemostasis
Department for Hematology and Coagulation Disorders, Skåne University Hospital
Skåne University Hospital
Katharine Dormandy Haemophilia Centre and Thrombosis Unit
Royal Free Hospital
Manchester Haemophilia Comprehensive Care Centre (Children’s and Adult’s)
Manchester Royal Infirmary and Manchester Children’s Hospital
Oxford Haemophilia Centre and Thrombosis Centre
Churchill Hospital
Sheffield Haemophilia and Thrombosis Centre
Royal Hallamshire Hospital
Hemophilia of Georgia has stood with us for over three decades, playing an early role in distributing donated factor via the WFH Humanitarian Aid program. Our relationship has deepened over the years as they continued to support this program and came on board as a founding Chapter Challenge champion in 2016. Their belief in educating future leaders is clear in their investment in the Youth Leadership Workshops, which has led to the training of over 50 young adults. They also support workshops devoted to educating providers and patient leaders on how to collect and use data to advocate for better patient care. Their staff generously volunteer their time as trainers and as well as serving on various committees.
The National Hemophilia Foundation helps advance our mission on several fronts. They inspire others to follow their lead as a founding champion of the NHF Chapter Challenge. Their commitment to equality of access is demonstrated in their support of the Cornerstone Initiative, which lays the foundation for care in the world's most underserved regions, as well as programs that aim to raise awareness and improve care of women with bleeding disorders and those with von Willebrand disease. We also benefit from their steadfast engagement with various programs including the WFH Twinning Program and their individual leaders’ contribution to our leadership and committees.
Do you sometimes wish you could do more? A bequest is a simple way for you to make a significant gift without changing anything about your financial security and lifestyle today. Your legacy will sustain care for the generations to come.
Download these sample clauses to give to your legal advisor.
We understand if you prefer to remain anonymous, but we would be very honoured if you would let us know of your intentions so that we may thank you personally. We would also be happy to answer any questions you may have or give you additional information. Please contact Jennifer Laliberté at 514‑875‑7944 ext.2822 or [email protected].
The information on the WFH USA website is provided for general information purposes only. The WFH USA does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH USA recommends that you contact your physician or local treatment centre. Before administering any products, the WFH USA urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
While every effort has been made to ensure the accuracy of the information on this site, the WFH USA does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.
Messages posted to WFH USA discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH USA social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH USA recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.
References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH USA. The WFH USA is not responsible and assumes no liability for the content of any linked websites.
The WFH USA does not collect personally identifying information about you when you visit our site, unless you choose to provide such information to us. Providing such information is strictly voluntary. This policy is your guide to how we will handle information we learn about you from your visit to our website.
Throughout our website, we provide links to other servers which may contain information of interest to our readers. We take no responsibility for, and exercise no control over, the organizations, views, or accuracy of the information contained on other servers. When linking to the WFH USA, we request that you ensure that there are no associated connections for commercial purposes. Any official use of the name WFH USA or the use of its logo needs to be approved by the WFH USA. If you have a link you’d like us to consider adding to our website, please send an email to [email protected] with the subject “Link request.”
All information, photographs, graphics, and other material on this website are protected by copyright. While users of this website may use the content for personal, non-commercial use, none of the content of this website can be modified, translated, transferred or sold, copied, reproduced, published, or distributed, in whole or in part, without the prior written consent of the WFH USA. To view a copy of the WFH USA’s permissions guidelines, click here.
The WFH USA encourages the dissemination of its information and welcomes proposals on the reprinting, redistribution, and translation of its materials. If you would like to publish information that you find on our website, please send your request to [email protected].
If you have suggestions on how to make the site more accessible, please contact us at [email protected].
Our website provides users the opportunity to opt-out of receiving communications from us through a special online form or via the communication they have received. You may, at all times, choose to receive which communications within the organization you can receive or none at all. You may also update your contact information previously provided to us via another online form.
If you have any questions about this privacy statement, the practices of this site, or your dealings with this website, you can contact us at [email protected].
The WFH USA has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH USA staff or falsely stating that they are associated with the WFH USA. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH USA, are fraudulent and come from outside of our organization.
If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH USA emails come from @wfhusa.org or @wfh.org).
We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH USA at [email protected] or call 1-877-417-7944.
Burlington, Ontario | Burlington Brant Street Pier |
Calgary, Alberta | Calgary Tower (April 16th) |
Calgary, Alberta | TELUS Spark Building |
Charlottetown, P.E.I. | Charlottetown City Hall |
Guelph, Ontario | Guelph Market And Square Fountain |
Kingston, Ontario | Kingston City Hall |
Lethbridge, Alberta | Lethbridge City Hall |
London, Ontario | London City Hall |
The fountain at the Forks | |
JA Taylor Building at Wellington and Dundas | |
Canada Life building | |
RBC Place London | |
Mississauga, Ontario | Civic Centre Clock Tower |
Newmarket, Ontario | Riverwalk Commons and the Fred A. Lundy Bridge |
Niagara Falls, Ontario | Niagara Falls (10PM EST for 15 minutes) "Watch it live!" |
Red Deer, Alberta | Red Deer City Hall |
Saskatoon, SK | Saskatel Centre |
St. Johns City, Newfoundland | St. Johns City hall, NFD |
Toronto, Ontario | CN Tower "Watch it live!" |
Vancouver, BC | Queen Elizabeth Theatre Tower |
Sails of Light Canada Place | |
BC Place | |
Vancouver City Hall | |
Science World |
Niagara Falls, New York | Niagara Falls (10PM EST for 15 minutes) "Watch it live!" |
Boston, Massachusetts | Zakim Bridge in Boston |
Longfellow Bridge in Boston | |
Davenport, Iowa | DavenPort Skybridge, Iowa |
Gilbert, Arizona | Gilbert Tower, Arizona |
Houston, Texas | Transwestern hq |
Milwaukee, Wisconsin | Pfister Hotel |
Minneapolis, Minnesota | Lowry Avenue Bridge |
I-35W Saint Anthony Falls Bridge | |
New York City, New York | Helmsley Building 230 Park Avenue building |
Oklahoma City, Oklahoma | Skydance bridge |
Poughkeepsie, New York | Mid-Hudson Bridge |
Scottsdale, Arizona | Talking Stick Resort |
Weymouth, Massachusetts | Fore River Bridge in Quincy/Weymouth |
Worcester, Massachusetts | Burns Bridge in Worcester |
Buenos Aires, Argentina | Planetario |
La Torre Monumental | |
Monumento Plaza Congreso | |
Palacio Lezama |
Australian Capital Territory | Shine Dome |
Royal Australian Mint | |
The Carillion | |
New South Wales | Newcastle City Hall Clock Tower |
Northern Territory | Darwin Convention Centre |
Queensland | Breakfast Creek Bridge, Newstead, Brisbane City Council |
Brisbane City Town Hall | |
CBD Tree Lights, Maronoa | |
Central Park Boardwalk, Townsville | |
Court House Gallery, Cairns Regional Council | |
George Roberts Bridge, Townsville | |
Heritage Façade Council building, Rockhampton | |
Ipswich Civic Centre, Ipswich City Council | |
Kurilpa Bridge, QGAO | |
Little Fletcher Bridge, Townsville | |
Old Magistrates Court House, Townsville | |
Parliament House, Brisbane | |
Reddacliff Place sculptures, Brisbane City Council | |
Sandgate Town Hall, Brisbane City Council | |
Stanthorpe Administration Building, Southern Downs Regional Council | |
Story Bridge, Brisbane City Council | |
Town Hall Warwick Clock Face, Southern Downs Regional Council | |
Townsville Sign | |
Transurban Gateway Bridge QLD | |
Treasury Casino, Brisbane | |
Victoria Bridge, Brisbane City Council | |
Victoria Bridge, Toowoomba | |
Victoria Bridge, Townsville | |
Warwick Town Hall roof lights, Southern Downs Regional Council | |
Water Towers, Logan | |
Wharton Reef Lighthouse, Townsville | |
Wickham Terrace Car Park architectural wall, Brisbane City Council | |
South Australia | The New Riverbank Lighting Feature |
Tasmania | Launceston Town Hall |
Victoria | Ballarat Town Hall Clock and Fountain |
Geelong intersection Moorabool & Malop St Geelong | |
Bolte Bridge Melbourne | |
Drum Theatre Dandenong | |
Western Australia | Mandurah bridge |
Mount Street Bridge | |
North Bridge Tunnel | |
Optus Stadium | |
Sky Ribbon | |
The Bell Tower, Perth |
Leicester | Leicester Royal Infirmary (Victoria Building) |
Mumbai | Chhatrapati Shivaji Maharaj International Airport (Terminal 2) |
Panama | Conjunto Monumental Histórico de Panamá Viejo |
Edificio de la Administración del Canal de Panamá | |
Tribunal Electoral | |
Hospital del Niño | |
Caja de Ahorros | |
Capital Bank | |
Compañía de Seguros Assa | |
IPHE |
Taipei City | Farglory Financial Center |
If you’re aware of a landmark that is lighting up red for World Hemophilia Day 2022 that is not on this list, please forward the official confirmation from the landmark to [email protected] to have it added to the list.
2012 | Christine Lee United Kingdom |
2006 | Dr. Bruce Evatt United States |
2012 | Piet de Kleijn The Netherlands |
2010 | Dr. Mammen Chandy India |
2008 | Dr. Man-Chiu Poon Canada |
2006 | Dr. Norma de Bosch Venezuela |
2004 | Dr. Parttraporn Insarangkura Thailand Dr. Carol K. Kasper United States |
University of North Carolina Hemophilia & Thrombosis Center
Nationwide Children’s Hospital
Gulf States Hemophilia and Thrombophilia Center
University of Texas Health Science Center at Houston
Orthopaedic Hemophilia Treatment Center
Mount Sinai School of Medicine
Mount Sinai Medical Center
Mayo (Rochester) Comprehensive Hemophilia Center, and International Hemophilia Training Center (WFH)
Mayo Clinic/Foundation and Mayo Medical School
Hemophilia & Thrombosis Treatment Center
University of California San Diego
2019 | Yogyakarta / Solo (Indonesia) – Utrecht (Netherlands) |
2018 | Abidjan (Ivory Coast) – Brussels (Belgium) |
2017 | Santa Cruz de la Sierra (Bolivia) – Buenos Aires (Argentina) |
2016 | Kampala (Uganda) – London (UK) |
2015 | Varna (Bulgaria) – Bonn (Germany) |
2014 | Arequipa (Peru) – Los Angeles (USA) |
2013 | Davangere (India) – Liverpool (UK) Ludhiana (India) – Detroit (USA) |
2012 | Hanoi (Vietnam) – Melbourne (Australia) |
2011 | Manado (Indonesia) – Utrecht (Netherlands) |
2010 | Delhi (India) – Winnipeg (Canada) Yaoundé (Cameroon) – Geneva (Switzerland) |
2009 | Chisinau (Moldova) – Warsaw (Poland) Colombo (Sri Lanka) – Vellore (India) |
2008 | Gaborone (Botswana) – Philadelphia (USA) |
2007 | Vientiane (Laos) – Brest (France) Damascus (Syria) – Montpellier (France) |
2006 | Lima (Peru) – Fort Worth (USA) |
2005 | Yerevan (Armenia) – Minneapolis (USA) Casablanca (Morocco) – Caen (France) |
2004 | Beirut (Lebanon) – Geneva (Switzerland) Santo Domingo (Dominican Republic) – Caracas (Venezuela) |
2003 | Cairo (Egypt) – Knoxville (USA) |
2002 | Moscow (Russia) – Liverpool (UK) Panama – Valencia (Spain) |
2001 | Bangalore (India) – St. Louis (USA) |
2000 | Pune (India) – Bradford (UK) |
1999 | Montevideo (Uruguay) – Buenos Aires (Argentina) Tianjin (China) – Calgary (Canada) |
1998 | Plovdiv (Bulgaria) – Bonn (Germany) |
1997 | Bogota (Colombia) – Los Angeles (USA) Tartu (Estonia) – Stockholm (Sweden) |
1996 | Timisoara (Romania) – Munich (Germany) Riga (Latvia) – Munster (Germany) |
1995 | Klaipeda (Lithuania) – Malmo (Sweden) |
1994 | Bratislava (Slovakia) – Tel Hashomer (Israel) |
2019 | Madagascar – Brittany (France) |
2018 | Kenya – Scotland |
2017 | Mongolia – Manitoba (Canada) |
2016 | Tanzania – Ontario (Canada) |
2015 | Bangladesh – Canada |
2014 | Nicaragua – Quebec (Canada) |
2013 | Mauritius – South Africa |
2012 | Vietnam – Ireland |
2011 | Cambodia – New Zealand |
2010 | Tunisia – Quebec (Canada) |
2009 | Peru – Galicia (Spain) |
2008 | South Africa – Canada |
2007 | Honduras – Georgia (USA) |
2006 | Bosnia and Herzegovina – Ireland |
2005 | Pakistan – Malaysia |
2004 | Dominican Republic – Venezuela |
2003 | Jordan – Toronto (Canada) |
2002 | Nicaragua – Venezuela |
2001 | Philippines – Victoria (Australia) |
2000 | Georgia – Minnesota (USA) Uruguay – Argentina |
1999 | Nepal – Sweden Mexico – Texas (USA) |
1998 | Latvia – Germany |
1997 | India – Denmark |
1995 | Israel – Slovakia |
2021 | Axel Seuser Germany |
2019 | Dr. Adolfo Llinás Colombia |
2017 | Pamela Hilliard Canada |
2015 | Kathy Mulder Canada |
2013 | James Luck United States |
2012 | Piet de Kleijn The Netherlands |
2011 | Dr. Lily Heijnen The Netherlands |
2010 | Dr. Horacio Caviglia Argentina |
2009 | Jerome D. Wiedel United States |
2008 | Dr. Federico Fernández-Palazzi Venezuela |
2007 | Michael Heim Israel |
2006 | Brenda Buzzard United Kingdom |
2005 | Dr. Marvin Gilbert United States |
2021 | Baolai Hua Yangzhou College, Xuzhou Medical University |
The effects of intra-articular injection of TNF-alpha Antagonists in treatment of haemophilic synovitis |
2019 | Maarten Eerdekens Belgium |
Association between multi-segment foot kinetics and blood induced joint damage in adult patients with hemophilic ankle arthropathy |
2017 | Fabio Souza Brazil |
Decrease in joint inflammation, swelling and pain after a swimming protocol in animal model of experimental-induced hemarthrosis |
2015 | SM Javd Mortazavi Iran |
Bilateral total knee arthroplasty in patients with hemophilia: A safe and cost-effective procedure |
2013 | Lize F.D. van Vulpen United States |
A fusion protein of IL4 and IL10, is equally effective in protecting cartilage from blood-induced damage compared to the individual components |
2012 | Horacio Caviglia Argentina |
Pseudotumor Surgery in Haemophilia A patients: Comparitive results between inhibitor and non-inhibitor patients |
2011 | Nick Goddard United Kingdom and Monique van Meegeren The Netherlands |
Early onset administration of IL-4 and IL-10 prevents blood-induced cartilage damage in vitro |
2010 | Lydia Abad-Franch Spain |
Influence of an Aquatic Training Protocol on the Reduced Risk of Cardiovascular Morbidity and Mortality in a Hemophiliac |
2009 | Sebastien Lobet Belgium |
Impact of Hemophilia Ankle Arthropathy on Gait Disability: Analysis of Energetic and Mechanical Variables |
2008 | Jose Alberto Tlacuilo-Parra Mexico |
Bone Turnover Markers and Bone Mineral Density in Children with Hemophilia |
2007 | Natalie Jansen The Netherlands |
Protective Abilities of Interleukin-10 in Blood-induced Cartilage Damage |
2006 | Axel Seuser and E. Kusch Germany |
Multi-Center Study of Orthopedic Outcome of the Lower Extremities in 249 Children with Hemophilia |
2005 | Frank van Genderen, Nico van Meeteren, Lily Heijnen, Piet de Kleijn, Marijke van den Berg, Paul Helders The Netherlands |
The Hemophilia Activities List: Final development and validation of a hemophilic-specific self-assessment questionnaire on functional abilities |
2004 | Goris Roosendaal, Zalima N Jahangier, Kim MG Jacobs, Johannes WJ Bijlsma, Floris PJG Lafeber The Netherlands |
Radiosynoviorthesis using YTTRIUM-90 results in adverse direct effects on cartilage: a human in vitro study |
2003 | Axel Seuser, Thomas Wallny, Günter Schumpe, Elmar Trunz, Hans-Hermann Brackman Germany |
How to advise young haemophiliacs to find the right sport? A new and safe algorithm |
2002 | James Luck, Jr. and Mauricio Silva United States |
Long-Term Review of Total Knee Arthroplasty |
2001 | Federico Fernández-Palazzi Venezuela |
Oxytetracycline Chlorohydrate: A new material for chemical synovial orthoses |
2000 | Horacio Caviglia Argentina |
Pseudotumours |
1999 | William J. Ribbans and J.L. Hicks United Kingdom |
Communication and Co-operation for the New Millennium – The Future of the Musculoskeletal Committee in the 21st Century |
1998 | Adolfo Llinas, Mauricio Silva, Monica Duarte, Gonzalo Ucros, Graciela Perini, Angela Maria Cerquera, Andres Forero Colombia |
Chromic phosphate synoviorthesis without age restriction should be the first treatment option for chronic active hemophilic synovitis |
2012 | Martha Patricia Monteros Rincon Mexico |
2010 | Antonia Luque de Garrido |
2008 | Jean Michel Bouchez |
2006 | Yuri Zhulyov |
2004 | Ashok Verma |